EBIT: Income before interest and taxes.
Zentalis Pharmaceuticals, Inc. (ZNTL) had EBIT of $-37.85M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-35.35M |
|
-- |
|
-- |
|
$37.85M |
|
$-37.85M |
|
$2.62M |
|
$-35.23M |
|
$-35.23M |
|
$-35.35M |
|
$-35.35M |
|
$-35.35M |
|
$-35.35M |
|
|
EBIT |
$-37.85M |
$-37.93M |
|
70.26M |
|
70.26M |
|
$-0.50 |
|
$-0.50 |
|
| Balance Sheet Financials | |
$218.10M |
|
$2.65M |
|
$34.97M |
|
$253.07M |
|
$35.24M |
|
-- |
|
$35.15M |
|
$70.39M |
|
$182.68M |
|
$182.68M |
|
$182.68M |
|
71.16M |
|
| Cash Flow Statement Financials | |
$-32.96M |
|
$30.01M |
|
$-1.12M |
|
$38.62M |
|
$34.56M |
|
$-4.07M |
|
$3.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-32.99M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.35% |
|
-19.35% |
|
-13.97% |
|
-19.35% |
|
$2.57 |
|
$-0.47 |
|
$-0.47 |
|